BioTime has a very large portfolio of intellectual property related to stem cells, regenerative medicine and tissue engineering. Our intellectual property portfolio is comprised of patents issued or applied for by BioTime and our subsidiaries (subsidiary patents are listed on their websites). We also license a number of patents from other institutions.
While the Company has included patent applications in these lists, such inclusion should not be construed to mean that the claims presented in these patent applications are currently enforceable. Only claims of issued patents are enforceable.